Could Adamas Pharmaceuticals Inc (ADMS) See a Reversal After This Very Strong Session?

September 17, 2017 - By Marie Mckinney

The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) is a huge mover today! The stock increased 4.82% or $0.99 on September 15, reaching $21.53. About 1.18 million shares traded. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has declined 0.40% since September 17, 2016 and is downtrending. It has underperformed by 17.10% the S&P500.
The move comes after 7 months positive chart setup for the $484.73M company. It was reported on Sep, 17 by Barchart.com. We have $22.61 PT which if reached, will make NASDAQ:ADMS worth $24.24M more.

Investors wait Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to report on November, 2. its quarterly earnings Wall Street analysts expect $-1.06 earnings per share, down $0.40 or 60.61 % from last year’s $-0.66 same quarter earnings. Adamas Pharmaceuticals Inc’s Wall Street analysts see 13.98 % negative EPS growth, taking into account the $-0.93 EPS reproted in the previous quarter,

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Ratings Coverage

Among 8 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 7 have Buy rating, 1 Sell and 0 Hold. Therefore 88% are positive. Adamas Pharmaceuticals had 20 analyst reports since August 7, 2015 according to SRatingsIntel. The company was initiated on Friday, April 1 by JMP Securities. The firm has “Buy” rating by Mizuho given on Thursday, June 16. The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) earned “Buy” rating by Aegis Capital on Tuesday, September 22. The stock has “Buy” rating by Mizuho on Thursday, September 8. The firm has “Buy” rating given on Tuesday, June 6 by Mizuho. The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has “Buy” rating given on Friday, August 25 by Mizuho. The firm has “Sell” rating given on Friday, October 16 by TheStreet. As per Tuesday, January 19, the company rating was initiated by Cowen & Co. The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has “Market Outperform” rating given on Friday, August 25 by JMP Securities. As per Friday, June 17, the company rating was initiated by Noble Financial.

More notable recent Adamas Pharmaceuticals Inc (NASDAQ:ADMS) news were published by: Marketwatch.com which released: “Adamas Pharma says its new Parkinson’s drug isn’t just a more expensive, long …” on August 29, 2017, also Fool.com with their article: “Why Urban Outfitters, Pure Storage, and Adamas Pharmaceuticals Jumped Today” published on August 25, 2017, Nasdaq.com published: “Adamas to Host Investor and Analyst Meeting on September 18, 2017” on September 13, 2017. More interesting news about Adamas Pharmaceuticals Inc (NASDAQ:ADMS) were released by: Seekingalpha.com and their article: “Adamas Pharmaceuticals: Still Upside After Big Rally” published on August 27, 2017 as well as Marketwatch.com‘s news article titled: “Adamas Pharma shares soar on Parkinson’s dyskinesia drug approval” with publication date: August 24, 2017.

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The company has market cap of $484.73 million. The Firm is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It currently has negative earnings. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.